the Image

Open Cancer Clinical Trials

The University of Chicago Medicine Comprehensive Cancer Center is leading the way in biomedical discoveries that will help physicians fight cancer more effectively. Our dedicated researchers and clinicians are conducting clinical trials in phases I, II, III and IV, leading to the development of new and better treatments. To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Multiple Myeloma Cancer Clinical Trials
Interventional only

Phase III
Study No PI Title
IRB15-1286 Jakubowiak, Andrzej Phase III Randomized Trial of Carfilzomib, Lenalidomide, Dexamethasone versus Lenalidomide Alone after Stem-Cell Transplant for Multiple Myeloma Details
Phase II
Study No PI Title
IRB16-0887 Jakubowiak, Andrzej Phase II, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
IRB16-1509 Jakubowiak, Andrzej Phase II, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation
IRB16-0567 Jakubowiak, Andrzej A Phase II, Multicenter, Open-Label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION MM-003). Details
IRB15-0406 Jakubowiak, Andrzej A Phase 2b, Open-Label, Single-Arm Study Of Selinexor (KPT-330) Plus Low-Dose Dexamethasone In Patients With Multiple Myeloma Quad-Refractory To Previous Therapies. Details
IRB14-0899 Jakubowiak, Andrzej Phase II Randomized Trial of Continuation of Post-Transplant Maintenance with Single-Agent Lenalidomide vs. Consolidation/Maintenance with Ixazomib-Lenalidomide-Dexamethasone in Patients with Residual Myeloma Details
IRB14-0624 Jakubowiak, Andrzej A Phase 1/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hematological Malignancies Details
IRB12-1088 Jakubowiak, Andrzej Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment with Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects with Relapsed and Relapsed/Refractory Multiple Myeloma Details
Phase I
Study No PI Title
IRB15-1438 Jakubowiak, Andrzej A Phase I First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects with Relapsed or Refractory Multiple Myeloma. Details
IRB15-0995 Jakubowiak, Andrzej An Open-Label, Multicenter, Phase 1b Study Of JNJ-54767414 (HuMax® CD38) (Anti-CD38 Monoclonal Antibody) In Combination With Backbone Regimens For The Treatment Of Subjects With Multiple Myeloma. Details
IRB14-0624 Jakubowiak, Andrzej A Phase 1/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hematological Malignancies Details
IRB12-1088 Jakubowiak, Andrzej Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment with Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects with Relapsed and Relapsed/Refractory Multiple Myeloma Details
Others
Study No PI Title
10-551-B Bishop, Michael Pilot study T cell depletion in the setting of autologous stem cell transplantation for patients with multiple myeloma Details
IRB16-1661 Jakubowiak, Andrzej Clinical-grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell Malignancies (MMRF-002)
10-064-B Godley, Lucy Molecular characterization of hematopoietic malignancies
11506A Jakubowiak, Andrzej Collection of Bone Marrow Samples from Patients with Multiple Myeloma who Already are Undergoing a Bone Marrow Biopsy and Aspirate


Although our objective is to provide on updated listings of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.

Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT Team .